AU2003258550A1 - Splicing-variant of the human p53 protein and use thereof in the production of pharmaceutical preparations for treating tumoural diseases - Google Patents

Splicing-variant of the human p53 protein and use thereof in the production of pharmaceutical preparations for treating tumoural diseases

Info

Publication number
AU2003258550A1
AU2003258550A1 AU2003258550A AU2003258550A AU2003258550A1 AU 2003258550 A1 AU2003258550 A1 AU 2003258550A1 AU 2003258550 A AU2003258550 A AU 2003258550A AU 2003258550 A AU2003258550 A AU 2003258550A AU 2003258550 A1 AU2003258550 A1 AU 2003258550A1
Authority
AU
Australia
Prior art keywords
splicing
variant
protein
treating
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003258550A
Inventor
Alf Giese
Ella L. Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitatsklinikum Hamburg Eppendorf
Original Assignee
Universitatsklinikum Hamburg Eppendorf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitatsklinikum Hamburg Eppendorf filed Critical Universitatsklinikum Hamburg Eppendorf
Publication of AU2003258550A1 publication Critical patent/AU2003258550A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU2003258550A 2002-07-30 2003-07-30 Splicing-variant of the human p53 protein and use thereof in the production of pharmaceutical preparations for treating tumoural diseases Abandoned AU2003258550A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10234739.5 2002-07-30
DE2002134739 DE10234739A1 (en) 2002-07-30 2002-07-30 New interfering splice variant of human p53 protein, useful for identifying modulators of p53 function, and potential anticancer agents
PCT/EP2003/008442 WO2004016788A1 (en) 2002-07-30 2003-07-30 Splicing-variant of the human p53 protein and use thereof in the production of pharmaceutical preparations for treating tumoural diseases

Publications (1)

Publication Number Publication Date
AU2003258550A1 true AU2003258550A1 (en) 2004-03-03

Family

ID=30128529

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003258550A Abandoned AU2003258550A1 (en) 2002-07-30 2003-07-30 Splicing-variant of the human p53 protein and use thereof in the production of pharmaceutical preparations for treating tumoural diseases

Country Status (3)

Country Link
AU (1) AU2003258550A1 (en)
DE (1) DE10234739A1 (en)
WO (1) WO2004016788A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1921882A (en) 2003-12-30 2007-02-28 莫洛根股份公司 Allogeneic tumor therapeutic agent
WO2009029054A1 (en) * 2007-08-31 2009-03-05 Agency For Science, Technology And Research P53 isoform gene(s) and uses thereof
EP2272979A1 (en) * 2009-06-30 2011-01-12 Centre National de la Recherche Scientifique (CNRS) Method for testing a subject thought to be predisposed to having cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19737562A1 (en) * 1997-08-28 1999-05-06 Otogene Biotechnologische Fors Method for the identification of interactions between proteins or peptides

Also Published As

Publication number Publication date
DE10234739A1 (en) 2004-02-12
WO2004016788A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
EP1578421A4 (en) Pharmaceutical preparations for treatments of diseases and disorders of the breast
AU2003264282A1 (en) Phenethanolamine derivatives and their use in the treatment of respiratory diseases
AU2003210321A1 (en) Use of sugar esters in cosmetic and/or pharmaceutical preparations
AU2002327792A1 (en) Diagnosis and treatment of diseases caused by mutations in cd72
AU2003265225A1 (en) Preparations for topical skin use and treatment
AU2003206311A1 (en) Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
AU2003206310A1 (en) Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
AU2002246152A1 (en) Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
AU2002233288A1 (en) Combined use of Enzyme Inhibitors and Pharmaceutical Preparations thereof for the Treatment and Prophylaxis of Arteriosclerosis, for the Treatment and Prevention of Allergic Reactions of Type I According to the Gell and Coombs Classification, and for the Treatment and Prevention of Dermatological Diseases Associated with FO
AU2003222347A1 (en) Novel peptide derivatives, preparation and therapeutic and cosmetic application thereof
AU2003268531A1 (en) Materials and methods for treatment of allergic diseases
AU2002346504A1 (en) Therapeutic protein and treatments
AU2003267532A1 (en) PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF Alpha-SYNUCLEIN-RELATED DISEASES
IL166706A0 (en) Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
AUPQ344799A0 (en) Treatment of respiratory diseases and infections
AU2003258550A1 (en) Splicing-variant of the human p53 protein and use thereof in the production of pharmaceutical preparations for treating tumoural diseases
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003291238A1 (en) Moringa esters and cosmetic and pharmaceutical preparations and methods of manufacture thereof
AU2003251303A1 (en) Pharmaceutical products and methods of manufacture
AU2003270350A1 (en) Isoxazoles and their use in the treatment of ischemic diseases
AU2003271016A1 (en) Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis
AU2002364757A1 (en) Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases
AU2003288127A1 (en) DIAGNOSTIC AND THERAPEUTIC USE OF H-Rev107 PROTEIN FOR ALZHEIMER DISEASE

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase